Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan

Clinical Cancer Research

Volumn 11, Issue 21, 2005, Pages 7800-7806

  Van Erp, Nielka P H ^a   Baker, Sharyn D ^b   Zhao, Ming ^b   Rudek, Michelle A ^b   Guchelaar, Henk Jan ^a   Nortier, Johan W R ^a   Sparreboom, Alex ^c   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; CYTOCHROME P450 3A4; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ISOSILYBIN A; ISOSILYBIN B; PLANT EXTRACT; SILIBININ; SILICRISTIN; SILIDIANIN; SILYBIN A; SILYBIN B; SILYBUM MARIANUM EXTRACT; SILYMARIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALTERNATIVE MEDICINE; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG INFUSION; ENDOMETRIUM CANCER; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SILYBUM MARIANUM; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CARCINOMA; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MILK THISTLE; NEOPLASMS; PLANT EXTRACTS; TIME FACTORS;

EID: 27744523714     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1288     Document Type: Article

References (37)

1. Astin JA. Why patients use alternative medicine: results of a national study. JAMA 1998;279:1548-53.
2. Boon H, Stewart M, Kennard MA, et al. Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 2000;18:2515-21.
3. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004;(343):1-19.
4. DiGianni LM, Garber JE, Winer EP. Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 2002;20:34-8S.
5. Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82.
6. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-14.
7. Cassileth BR, Lusk EJ, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine. A study of patients, treatments, and practitioners. Ann Intern Med 1984;101:105-12.
8. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-503.
9. De Smet PA. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004;76:1-17.
10. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9.
11. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. Induction of imatinib metabolism by Hypericum perforatum. Blood 2004;104:1229-30.
12. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-9.
13. Rambaldi A, Jacobs B, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2005;CD003620.
14. Blumenthal M. Herb sales down 7.4 percent in mainstream market. Herbal Gram 2005;66:63.
15. Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D, Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-13.
16. Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000;28:1270-3.
17. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000;86:250-6.
18. Zuber R, Modriansky M, Dvorak Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002;16:632-8.
19. Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyl-transferases. Drug Metab Dispos 2004;32:587-94.
20. Chrungoo VJ, Reen RK, Singh K, Singh J. Effects of silymarin on UDP-glucuronic acid and glucuronidation activity in the rat isolated hepatocytes and liver in relation to D-galactosamine toxicity. Indian J Exp Biol 1997;35:256-63.
21. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003;304:1258-67.
22. Nguyen H, Zhang S, Morris ME. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 2003;92:250-7.
23. Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21:807-14.
24. de Bruijn P, Willems EW, Loos WJ, Verweij J, Sparreboom A. Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples. Anal Biochem 2004;328:84-6.
25. Han YH, Lou HX, Ren DM, Sun LR, Ma B, Ji M. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process. J Pharm Biomed Anal 2004;34:1071-8.
26. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinscea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004;76:428-40.
27. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035-63.
28. Weyhenmeyer R, Mascher H, Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 1992;30:134-8.
29. Kim DH, Jin YH, Park JB, Kobashi K. Silymarin and its components are inhibitors of β-glucuronidase. Biol Pharm Bull 1994;17:443-5.
30. DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003;23:866-70.
31. Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002;22:551-6.
32. Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005;61:1-7.
33. Leber HW, Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung 1976;26:1603-5.
34. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002;20:3122-9.
35. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003;31:533-9.
36. Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002;20:3293-301.
37. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8.